Caxton Associates (New York)’s Biogen BIIB Stock Holding History

Caxton Associates (New York)’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-45,000	Closed	-$11.6M	–	467
2023 Q4	$11.6M	Buy	+45,000	New	+$11.1M	0.6%	43
2022 Q1	–	Sell	-2,332	Closed	-$559K	–	524
2021 Q4	$559K	Buy	+2,332	New	+$600K	0.06%	252
2020 Q4	–	Sell	-1,110	Closed	-$315K	–	155
2020 Q3	$315K	Sell	1,110 -222	-17%	-$61.9K	0.03%	189
2020 Q2	$356K	Sell	1,332 -3,943	-75%	-$1.19M	0.03%	205
2020 Q1	$1.67M	Buy	+5,275	New	+$1.6M	0.31%	25
2018 Q4	–	Sell	-5,867	Closed	-$2.07M	–	289
2018 Q3	$2.07M	Buy	+5,867	New	+$2.02M	0.14%	121
2018 Q2	–	Sell	-2,671	Closed	-$731K	–	376
2018 Q1	$731K	Sell	2,671 -195	-7%	-$60.5K	0.04%	222
2017 Q4	$913K	Buy	+2,866	New	+$919K	0.04%	221
2017 Q3	–	Sell	-1,500	Closed	-$407K	–	494
2017 Q2	$407K	Buy	1,500 +300	+25%	+$79.3K	0.02%	403
2017 Q1	$328K	Buy	+1,200	New	+$339K	﹤0.01%	334
2014 Q2	–	Sell	-10,000	Closed	-$3.06M	–	181
2014 Q1	$3.06M	Buy	+10,000	New	+$3.17M	0.19%	94

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Caxton Associates (New York)'s BIIB Position: Q1 2024 in Review

Caxton Associates (New York) sold out of Biogen (BIIB) in Q1 2024, closing a stake of 45,000 shares — an estimated $11.6M sold.

Caxton Associates (New York) first reported a position in BIIB in Q1 2014 and held it in 11 quarters. The position peaked at $11.6M in Q4 2023. 955 funds tracked by Wall St. Rank hold BIIB as of Q1 2024.

Caxton Associates (New York) reported no remaining Biogen position as of Q1 2024 after selling out during the quarter.
Caxton Associates (New York) sold 45,000 Biogen shares in Q1 2024, an estimated $11.6M.
Caxton Associates (New York) first reported a position in Biogen in Q1 2014 and held it in 11 quarters.
Caxton Associates (New York)'s Biogen position peaked at $11.6M in Q4 2023.
955 funds tracked by Wall St. Rank held Biogen as of Q1 2024.

Based on Caxton Associates (New York)'s 13F filing for Q1 2024, filed 15 May 2024.